Ohio is currently home to 3225 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Cincinnati, Columbus, Cleveland and Dayton. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
DEFIANCE: RCT of ClotTriever System Versus Anticoagulation In Deep Vein Thrombosis
NCT05701917
Recruiting
This study is a prospective, multicenter, randomized controlled trial of an interventional strategy using the ClotTriever System to achieve and maintain vessel patency (ClotTriever Intervention Arm) versus conservative medical management using anticoagulation therapy alone (Conservative Medical Management Arm) in the treatment of subjects with symptomatic unilateral iliofemoral DVT. The study will collect data on demographics, comorbidities, details from the DVT diagnosis and treatment, and clin... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/16/2025
Locations: Mercy Health - The Heart Institute, Cincinnati, Ohio
Conditions: Venous Thromboembolism, Deep Venous Thrombosis, Post-Thrombotic Syndrome
Register for Updates
A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus
NCT05620407
Recruiting
The purpose of this study is to evaluate the effectiveness and safety of deucravacitinib compared with placebo in an active moderate to severe Systemic Lupus Erythematosus (SLE) population.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/16/2025
Locations: University of Cincinnati Medical Center, Cincinnati, Ohio
Conditions: Systemic Lupus Erythematosus
Register for Updates
Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma
NCT05605899
Recruiting
The goal of this clinical study is to compare the study drug, axicabtagene ciloleucel, versus standard of care (SOC) in first-line therapy in participants with high-risk large B-cell lymphoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/16/2025
Locations: Oncology Hematology Care Clinical Trials, LLC, Cincinnati, Ohio
Conditions: High-risk Large B-cell Lymphoma (LBCL)
Register for Updates
Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer
NCT05502237
Recruiting
The primary objective of this study is to compare the effect of zimberelimab (ZIM) and domvanalimab (DOM) in combination with chemotherapy relative to pembrolizumab (PEMBRO) in combination with chemotherapy on overall survival (OS) in patients with untreated metastatic non-small cell lung cancer with no actionable genomic alteration.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/16/2025
Locations: Oncology Hematology Care, Inc., Cincinnati, Ohio
Conditions: Non-small Cell Lung Cancer
Register for Updates
Zemaira Eosinophilic Esophagitis Pilot Study
NCT05485155
Recruiting
This is a prospective, open-label drug study that will examine the effects of Zemaira (alpha-1 trypsin inhibitor) in patients with Eosinophilic Esophagitis.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
05/16/2025
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: Eosinophilic Esophagitis
Register for Updates
Testing a Combination of Vaccines for Cancer Prevention in Lynch Syndrome
NCT05419011
Recruiting
This phase IIb trial tests whether Tri-Ad5 in combination with N-803 works to prevent colon and other cancers in participants with Lynch syndrome. Each of the three injections in Tri-Ad5 vaccine contain a different substance that is in precancer and cancer cells. Injecting these substances may cause the immune system to develop a defense against cancer that recognizes and destroys any precancer and cancer cells that produce these proteins in the future. N-803 may increase immune responses to oth... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/16/2025
Locations: Cleveland Clinic Foundation, Cleveland, Ohio
Conditions: Lynch Syndrome, Colorectal Carcinoma, Colorectal Neoplasm
Register for Updates
A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
NCT05128825
Recruiting
This is a multi-part Phase 2 study to evaluate the efficacy and safety of azenosertib (ZN-c3) in subjects with Platinum-Resistant, High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. Part 2 of the study will be conducted in subjects whose tumors are Cyclin E1 positive as determined by central review using the Sponsor's investigational clinical trial assay.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/16/2025
Locations: Site 0147 - Trihealth Cancer Institute - Harold and Eugen, Cincinnati, Ohio
Conditions: High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Register for Updates
Reaching Rural Cancer Survivors Who Smoke Using Text-Based Program
NCT05008848
Recruiting
This phase III trial compares the effect of text-based cessation intervention to a manual in helping rural cancer patients who smoke, quit. Text-based scheduled gradual reduction may reduce the frequency of cigarette use to zero and may be effective in quitting smoking.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/16/2025
Locations: Strecker Cancer Center-Belpre, Belpre, Ohio
Conditions: Cigarette Smoking-Related Carcinoma
Register for Updates
Parkinson's Foundation PD GENEration Genetic Registry
NCT04994015
Recruiting
Development of a central repository for PD-related genomic data for future research.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/16/2025
Locations: University of Cincinnati, Cincinnati, Ohio
Conditions: Parkinson's Disease
Register for Updates
A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)
NCT04961996
Recruiting
This is a Phase III, global, randomized, open-label, multicenter, study evaluating the efficacy and safety of adjuvant giredestrant compared with endocrine therapy of physician's choice in participants with medium- and high-risk Stage I-III histologically confirmed estrogen receptor (ER)-positive and human epidermal growth factor receptor 2 (HER2)-negative early breast cancer. In addition, an open-label exploratory substudy will explore the safety and efficacy of giredestrant in combination wit... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/16/2025
Locations: Aultman Hospital, Canton, Ohio
Conditions: Early Breast Cancer
Register for Updates
A Clinical Trial Evaluating the Safety and Efficacy of a Single Subretinal Injection of AGTC-501 in Participants With XLRP
NCT04850118
Recruiting
This study will evaluate and compare the safety, efficacy, and tolerability of 2 doses of a recombinant adeno-associated virus vector (AGTC-501/laruparetigene zovaparvovec )) to an untreated control group in male participants with X-linked retinitis pigmentosa caused by RPGR mutations.
Gender:
MALE
Ages:
Between 12 years and 50 years
Trial Updated:
05/16/2025
Locations: Cincinnati Eye Institute, Cincinnati, Ohio
Conditions: X-Linked Retinitis Pigmentosa
Register for Updates
Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors
NCT04840589
Recruiting
This phase I/Ib trial is to find out the best dose, possible benefits and/or side effects of BET bromodomain inhibitor ZEN-3694 (ZEN003694) when given in combination with nivolumab with or without ipilimumab in treating patients with solid tumors. ZEN003694 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/16/2025
Locations: Case Western Reserve University, Cleveland, Ohio
Conditions: Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm, Recurrent Platinum-Resistant Ovarian Carcinoma, Refractory Ovarian Carcinoma
Register for Updates